TELO Telomir Pharmaceuticals Inc
Price (delayed)
$3.13
Market cap
$93.16M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.56
Enterprise value
$91.89M
We are a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic treatment for
Highlights
Telomir Pharmaceuticals's debt has plunged by 100% YoY
The quick ratio has grown by 16% from the previous quarter
Telomir Pharmaceuticals's equity has shrunk by 81% YoY but it has increased by 45% QoQ
Telomir Pharmaceuticals's EPS has increased by 32% QoQ but it has decreased by 17% YoY
Key stats
What are the main financial stats of TELO
Market
Valuations
Earnings
Shares outstanding
29.76M
Market cap
$93.16M
Enterprise value
$91.89M
Price to earnings (P/E)
N/A
Price to book (P/B)
144.13
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$12.24M
Net income
-$16.53M
EBIT
-$12.19M
EBITDA
-$12.19M
Free cash flow
-$5.07M
Per share
Balance sheet
Liquidity
EPS
-$0.56
EPS diluted
-$0.56
Free cash flow per share
-$0.17
Book value per share
$0.02
Revenue per share
$0
TBVPS
$0.04
Total assets
$1.32M
Total liabilities
$680,968
Debt
$0
Equity
$643,037
Working capital
$643,037
Debt to equity
0
Current ratio
1.94
Quick ratio
1.86
Net debt/EBITDA
0.1
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-829.7%
Return on equity
-1,166.5%
Return on invested capital
N/A
Return on capital employed
-1,896.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TELO stock price
How has the Telomir Pharmaceuticals stock price performed over time
Intraday
14.23%
1 week
-24.03%
1 month
-21.75%
1 year
-43.04%
YTD
-24.03%
QTD
-3.1%
Financial performance
How have Telomir Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$12.24M
Net income
-$16.53M
Gross margin
N/A
Net margin
N/A
The company's net income rose by 28% QoQ but it fell by 26% YoY
TELO's operating income is down by 17% since the previous quarter
Growth
What is Telomir Pharmaceuticals's growth rate over time
Valuation
What is Telomir Pharmaceuticals stock price valuation
P/E
N/A
P/B
144.13
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Telomir Pharmaceuticals's EPS has increased by 32% QoQ but it has decreased by 17% YoY
Telomir Pharmaceuticals's equity has shrunk by 81% YoY but it has increased by 45% QoQ
The price to book (P/B) is 34% less than the last 4 quarters average of 190.3
Efficiency
How efficient is Telomir Pharmaceuticals business performance
The return on assets has dropped by 53% year-on-year and by 2.9% since the previous quarter
The ROE has contracted by 12% YoY and by 7% from the previous quarter
Dividends
What is TELO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TELO.
Financial health
How did Telomir Pharmaceuticals financials performed over time
The total assets is 94% greater than the total liabilities
The total assets has dropped by 72% year-on-year but it has increased by 27% since the previous quarter
TELO's total liabilities is down by 49% year-on-year but it is up by 14% since the previous quarter
Telomir Pharmaceuticals's debt is 100% less than its equity
Telomir Pharmaceuticals's debt has plunged by 100% YoY
The company's debt to equity has shrunk by 100% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.